First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

By sjmartinez • April 18, 2025

Yap TA, Goldman JW, Vinayak S, Tomova A, Hamilton E, Naito Y, Giordano A, Bondarenko I, Yamashita T, Zhou L, Moreau A, Neumann H, Tougias J, Liu F, Park J, Delioukina M, Jhaveri K. First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer. Clin Cancer Res. 2025 Apr 17. doi: 10.1158/1078-0432.CCR-24-2740. Epub ahead of print. PMID: 40243688.

Tags: Hematology/Oncology, Publications

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]

Dedicated review of sarcoma pathology is necessary for corroborative diagnosis in nearly one half of referred patients

Eckardt MA, Siena NM, Copeland AR, McCaw TR, Shehata MS, Lofftus SY, Graham DS, Dao HB, Singh AS, Chmielowski B, Federman N, Kadera BE, Kalbasi[...]

ASO Visual Abstract: Impact of Screening Mammography on Breast Cancer Outcomes in Women Aged 80 Years and Over

Huang SY, Murray M, Rubio A, Okoro N, Sedrak MS, McCloskey SA, Jackson N, Teshome M, Kapoor NS. ASO Visual Abstract: Impact of Screening Mammography[...]